Rosenthal YS, Schwartz N, Sagy I, et al. - Receipt of biologic medications for psoriasis was associated with a statistically and clinically significant lower risk for developing PsA, thus, biologic medications should be considered for patients that present with significant risk factors for PsA at an earlier stage of treatment.

• A retrospective cohort study was conducted.

• Participants included patients who had received biological treatment for psoriasis and were not diagnosed with psoriatic arthritis prior to or at the time of biologic treatment start.

• Controls were matched by age at diagnosis, gender, time until treatment start, maximum BMI and smoking.

• Of 1326 cases, 663 had received biological treatment and 663 had not.

• Multivariable Cox regression revealed a significantly higher risk for PsA in the control group vs the biological treatment group (adjusted HR=1.39).